Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors
Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors
Increasing evidence indicates that factor VIII (FVIII) inhibitor bypassing agents (FEIBA® and NovoSeven®) can provide effective peri-operative haemostasis in haemophilia patients with high-responding inhibitors. We report the collected experience of all major and minor surgeries, conducted between December 1998 and September 2008, at four UK haemophilia Comprehensive Care Centres with FEIBA® as the first-line bypassing agent in patients with inhibitors. A total of 26 surgical procedures were performed in 18 patients of ages 34-83years including five patients with acquired FVIII inhibitors. A single pre-operative infusion of FEIBA was followed by 6-12h interval dosing for major surgeries at the discretion of the physician to approximate a maximum of 200Ukg-1day-1, with tapering when postoperative haemostasis and wound healing permitted. Haemostatic outcomes were retrospectively reviewed against European consensus thresholds for blood loss and duration of treatment compared with expectations for equivalent procedures in non-inhibitor patients. Peri-operative haemostatic outcome with FEIBA was rated excellent or good in 78% of 18 major surgeries in 12 patients, including 11 major orthopaedic procedures. Haemostatic outcome was rated excellent in all seven procedures in five patients with acquired FVIII inhibitors and in all eight minor surgical procedures in six patients. FEIBA was well tolerated with no intra-operative haemostatic complications. A single, transient postoperative thrombotic adverse event occurred in a patient with cerebrovascular disease. This case series adds significantly to existing evidence that FEIBA can provide adequate, well-tolerated, peri-operative haemostatic cover for a wide variety of major and minor surgical procedures.
Acquired inhibitor, Bypassing agents, FEIBA, Haemophilia, Inhibitors, Surgery
28-34
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Yee, T. T.
b268a19d-ef5f-47f2-af65-505bc03ed98d
Wilde, J.
1d1255bc-cc66-4650-a9b7-f7bb42e9d7d7
1 January 2011
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Yee, T. T.
b268a19d-ef5f-47f2-af65-505bc03ed98d
Wilde, J.
1d1255bc-cc66-4650-a9b7-f7bb42e9d7d7
Rangarajan, S., Yee, T. T. and Wilde, J.
(2011)
Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors.
Haemophilia, 17 (1), .
(doi:10.1111/j.1365-2516.2010.02360.x).
Abstract
Increasing evidence indicates that factor VIII (FVIII) inhibitor bypassing agents (FEIBA® and NovoSeven®) can provide effective peri-operative haemostasis in haemophilia patients with high-responding inhibitors. We report the collected experience of all major and minor surgeries, conducted between December 1998 and September 2008, at four UK haemophilia Comprehensive Care Centres with FEIBA® as the first-line bypassing agent in patients with inhibitors. A total of 26 surgical procedures were performed in 18 patients of ages 34-83years including five patients with acquired FVIII inhibitors. A single pre-operative infusion of FEIBA was followed by 6-12h interval dosing for major surgeries at the discretion of the physician to approximate a maximum of 200Ukg-1day-1, with tapering when postoperative haemostasis and wound healing permitted. Haemostatic outcomes were retrospectively reviewed against European consensus thresholds for blood loss and duration of treatment compared with expectations for equivalent procedures in non-inhibitor patients. Peri-operative haemostatic outcome with FEIBA was rated excellent or good in 78% of 18 major surgeries in 12 patients, including 11 major orthopaedic procedures. Haemostatic outcome was rated excellent in all seven procedures in five patients with acquired FVIII inhibitors and in all eight minor surgical procedures in six patients. FEIBA was well tolerated with no intra-operative haemostatic complications. A single, transient postoperative thrombotic adverse event occurred in a patient with cerebrovascular disease. This case series adds significantly to existing evidence that FEIBA can provide adequate, well-tolerated, peri-operative haemostatic cover for a wide variety of major and minor surgical procedures.
This record has no associated files available for download.
More information
Accepted/In Press date: 7 June 2010
e-pub ahead of print date: 29 December 2010
Published date: 1 January 2011
Keywords:
Acquired inhibitor, Bypassing agents, FEIBA, Haemophilia, Inhibitors, Surgery
Identifiers
Local EPrints ID: 442900
URI: http://eprints.soton.ac.uk/id/eprint/442900
ISSN: 1351-8216
PURE UUID: 289d565a-9d2f-4445-ac48-6cd2071c7782
Catalogue record
Date deposited: 30 Jul 2020 16:34
Last modified: 17 Mar 2024 04:02
Export record
Altmetrics
Contributors
Author:
T. T. Yee
Author:
J. Wilde
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics